跳至主要内容
临床试验/EUCTR2015-001317-28-NL
EUCTR2015-001317-28-NL进行中(未招募)1 期

A B2-agonist as a CFTR activator in CF - Part 2 - ABBA 2

MC Utrecht0 个研究点开始时间: 2015年5月19日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -CFTR genotype compound/A455E or compound/R117H
  • -Already had a rectal biopsy to produce an organoid
  • -Males and females, aged 18 years or older on the date of informed consent
  • -Signed informed consent form (ICF)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 20
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • -Severe acute exacerbation or pulmonary infection during last four weeks (needing intravenous treatment and/or systemic corticosteroids)
  • -Known cardiovascular medical history like cardiac failure, arrhythmias, ischemic cardiac disease, long QT interval syndrome and hypertension
  • -Known hyperthyroidism, thyrotoxicosis, galactose intolerance, lactase deficiency or glucose-galactose malabsorption
  • -Haemoglobin A1C (HBA1C) > 45 mmol/mol
  • -Use of oral B2-agonist one week prior to the start of the study (V1)
  • -Use of: heart glycoside, high dose sympathomimetics, theophylline, thiazide diuretics or non-selective beta-blockers
  • -Pregnancy or breastfeeding
  • -Participation in another drug-investigating clinical study at the start
  • -Inability to follow instructions of the investigator

研究者

发起方
MC Utrecht

相似试验